Skip to content

Gelsoft Vascular Graft

by Carbomedics, Inc.

PMA P890045

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None ongoing

2 closed

Documents

PMA P890045↗

FDA record

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA PMA, synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPRL NumberP890045 Date11 Jan 1993DecidedStatusActive

Recalls

2 recalls · FDA

  • 2 recalls, same reason

    • Terminated Z-1912-2015 FDA Class II initiated 15 May 2015
    • Terminated Z-1913-2015 FDA Class II initiated 15 May 2015

    Product was labeled as a 30cm graft, when in fact the graft in the box was a 15cm graft.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Full name
Vascutek Gelsoft(Tm) Vascular Graft
Trade Name
Gelseal Tm Triaxial Vascular Graft
Generic Name
GRAFT, VASCULAR, SYNTHETIC/BIOLOGIC COMPOSITE
PMA Number
FDA Product Code
MAL
Device Class
Class II
Regulation
21 CFR Part 870.3450
Advisory Committee
Cardiovascular
FDA Decision
APRL

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Gelsoft Vascular Graft is a synthetic/biologic composite vascular graft, designed as a replacement or bypass conduit for cardiovascular applications. It is classified as a Class II medical device under the FDA’s regulatory framework, intended for use in surgical procedures requiring durable vascular support.

This graft is supplied sterile and intended for single-use. It is manufactured in various sizes and configurations, as indicated by the registration numbers, and must be stored under appropriate conditions to maintain sterility. The device holds an FDA Premarket Approval (PMA) under PMA number P890045, with regulatory oversight under 21 CFR 870.3450 for vascular grafts.

Other devices from Carbomedics, Inc.

See all devices from Carbomedics, Inc. →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What types of cardiovascular procedures is the Gelsoft Vascular Graft intended to support as a replacement or bypass conduit?

    The Gelsoft Vascular Graft is designed specifically for surgical procedures requiring durable vascular support, such as arterial bypasses or replacements in cardiovascular applications. Its synthetic/biologic composite construction makes it suitable for use in contexts where long-term patency and structural integrity are critical, such as coronary, peripheral, or other vascular reconstructions.

  • Is the Gelsoft Vascular Graft reusable, or is it meant for single-use only? How should it be stored to maintain sterility?

    The Gelsoft Vascular Graft is explicitly intended for single-use only and is supplied sterile. To preserve sterility, it must be stored under appropriate conditions as specified by the manufacturer, typically in a sealed, sterile packaging until the time of use. Improper storage could compromise its integrity.

  • What sizes or configurations are available for the Gelsoft Vascular Graft, and how can I identify them?

    The Gelsoft Vascular Graft is manufactured in multiple sizes and configurations, each corresponding to specific registration numbers (e.g., 2246552, 9612515, 1640201, etc.). These identifiers help distinguish between diameters, lengths, or other variations. The exact sizing details should be referenced in the manufacturer’s documentation or catalog, as they are tailored to different surgical needs.

  • How was the regulatory approval process for the Gelsoft Vascular Graft structured, and what does the PMA number indicate?

    The Gelsoft Vascular Graft received FDA Premarket Approval (PMA) under PMA number P890045, which means it underwent a rigorous review process to ensure safety and effectiveness. The PMA was granted after submission to the FDA’s Cardiovascular (CV) Advisory Committee in 1989, with a final decision in 1993. This approval pathway is required for Class II devices like vascular grafts, ensuring compliance with 21 CFR 870.3450.